<DOC>
	<DOCNO>NCT01299558</DOCNO>
	<brief_summary>This study do look absolute bioavailability fluticasone furoate GW642444 inhalation powder administer healthy subject . Bioavailability determine measure amount dose inhale medication reach circulation ; amount inhale fluticasone furoate GW642444 powder compare medication administer intravenously ( bioavailability 100 % ) .</brief_summary>
	<brief_title>Study Look Compare How Inhaled Intravenous Fluticasone Furoate GW642444 Are Processed Body Healthy Subjects</brief_title>
	<detailed_description>Fluticasone furoate ( FF ) , novel glucocorticoid , GW642444 , potent , inhale longacting , beta2-receptor agonist ( LABA ) , currently development combination use once-daily , inhaled treatment asthma chronic obstructive pulmonary disease ( COPD ) . FF also develop stand-alone product asthma GW642444 also develop stand-alone product combination novel , long-acting muscarinic antagonist treatment COPD . This study perform determine absolute bioavailability FF GW642444 deliver combination novel dry powder inhaler .</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Healthy male female 18 64 year age inclusive Body mass index ( BMI ) within range 18.529 0 kg/m2 ( inclusive ) Subjects current nonsmoker AST , ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block , base single ECG value , average three ECGs obtain brief recording period No significant abnormality Holter ECG screen FEV1 ≥ 85 % predict screening . Capable give write informed consent , include compliance requirement restriction list consent form Subjects able use inhalation device satisfactorily As result medical interview , physical examination screen investigation , principal investigator delegate physician deems subject unsuitable study . Subjects must systolic blood pressure 145 mmHg diastolic pressure 85 mmHg Any history breathing problem adult life Pregnant lactating females The subject treat diagnosed depression within six month screen history significant psychiatric illness Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Subjects suffer low respiratory tract infection within 4 week screen visit Subjects recent history ( within 6 month ) pneumonia History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation Any adverse reaction include immediate delay hypersensitivity beta2agonist , sympathomimetic drug , intranasal , inhale , systemic corticosteroid therapy . Known suspected sensitivity constituent new powder inhaler ( i.e. , lactose magnesium stearate ) History milk protein allergy Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety The subject take oral corticosteroid le 8 week screen visit The subject take inhaled , intranasal topical steroid le 4 week screen visit History alcohol/drug abuse dependence within 12 month study The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) Exposure four new chemical entity within 12 month prior first dose day Where participation study would result donation blood blood product excess 500 mL within 56 day period A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . The subject test positive HIV antibodies A positive prestudy urine drug screen randomly test study Positive carbon monoxide ( CO ) alcohol breath test screen admission Unit . Positive urine cotinine test screen Consumption seville orange , pomelo ( member grapefruit family ) grapefruit juice 7 day prior first dose study medication Unwillingness inability follow procedure outline protocol Subject mentally legally incapacitate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>GW642444</keyword>
	<keyword>absolute bioavailability</keyword>
	<keyword>healthy subject</keyword>
	<keyword>fluticasone furoate</keyword>
	<keyword>GW685698</keyword>
</DOC>